Loading...
Loading...
Advaxis, Inc.
, a biotechnology company developing the next generation of
cancer immunotherapies, announced that the Japan Patent Office issued to
Advaxis two notices of allowance for two patent applications (P-72863-JP,
P-7924) with claims for each patent application related to the Company's
proprietary cancer immunotherapy platform technology. These patents will
provide protection in Japan until 2030.
Including these patents, Advaxis now has well over 40 patents issued and over
40 patents pending worldwide, all covering both core methodology and other
aspects of our proprietary immunotherapy technology platform.
One of the patent applications allowed by the Japan Patent Office covers
Advaxis's immunotherapy treatments targeting factors that are essential for
tumors or metastases to form new blood vessels (angiogenesis) or that are
expressed by tumor blood vessels. Inhibiting a tumor's blood supply is
necessary to prevent tumor growth. The claims allowed under this patent
application cover multiple targets associated with angiogenesis that can be
targeted at the same time in humans as well as animals. These targets include,
but are not limited to, HER2 and VEGFr2. In addition, the claims also cover
endoglin fragments (CD105A and CD105B) used to target formation of new tumor
blood vessels.
The second patent application that has now been allowed by the Japan Patent
Office covers the form of a recombinant attenuated auxotrophic Listeria having
specific mutations conferring attenuation along with plasmid that complements
the genomic mutation and also expresses a protein antigen fused to highly
immunogenic Listeria peptides or other strongly immunogenic
pathogen-associated peptide sequences. The claims allowed under this patent
application protect key elements of Advaxis's proprietary immunotherapy
platform technology in Japan.
"As we continue to expand our intellectual property portfolio of our
proprietary cancer immunotherapies, patents such as these are important to
protect the core elements of our technology and extend our protection in key
markets like Japan," commented Dr. Robert Petit, Chief Scientific Officer of
Advaxis. "It has already been established that attacking a tumor's blood
supply is an important strategy in preventing the tumor from growing and
spreading. The addition of these two patents in Japan further allows Advaxis
to protect key elements of its proprietary cancer immunotherapies."
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in